Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06804824 · ClinicalTrials.gov registry record · Phase 1

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Vividion Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
220
Enrollment target
9
Study locations

NCT06804824 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Vividion Therapeutics. The registered enrollment target is 220 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (12% higher). The trial reports 9 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06804824, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Vividion Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
220 participants
Enrollment target
9
Study locations

Study Summary

A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or trametinib in participants with advanced solid tumors.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG Trametinib
  • DRUG Sotorasib
  • DRUG VVD-159642

Study Locations (9)

Texas

  • NEXT Austin - Austin
  • NEXT Dallas - Irving
  • START San Antonio - San Antonio
  • NEXT San Antonio - San Antonio

Michigan

  • START Mid West - Grand Rapids

Utah

  • START Mountain - Ogden

Virginia

  • NEXT Virginia - Fairfax

South Australia

  • Clinical Research South Australia (CRSA) - Adelaide

Western Australia

  • Linear Clinical - Nedlands

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2025-02-25
Est. Completion 2027-08-01
Phase Phase 1

Sponsor

Vividion Therapeutics

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06804824

The ClinicalTrials.gov registry entry for NCT06804824 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (12% higher). The listed sponsor is Vividion Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 3 interventions - of which Trametinib is the first listed.

NCT06804824 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Texas, Michigan, Utah.

Frequently Asked Questions

What is clinical trial NCT06804824 about?

NCT06804824 is a clinical study titled "A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors". A FIH study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3Kα) inhibitor, as a single agent and in combination with either sotorasib or tra...

What is the current status of trial NCT06804824?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2025-02-25. Estimated completion is 2027-08-01.

What conditions does trial NCT06804824 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT06804824?

The interventions under investigation include: Trametinib (DRUG), Sotorasib (DRUG), VVD-159642 (DRUG).

Who is sponsoring clinical trial NCT06804824?

This trial is sponsored by Vividion Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06804824 being conducted?

This trial has 9 study locations across Michigan, Texas, Utah, Virginia, South Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Michigan

All trials with a study site in Michigan

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.